Correction

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 2016;43:504-11. In the Materials and Methods section, fifth paragraph, this sentence should read as follows:

A minimal clinically important difference (MCID) in HAQ-DI was defined as a change from baseline of ≤ –0.22. [Not ≥ –0.22.]

We regret the error.

doi:10.3899/jrheum.150613.C1

Downloaded on April 17, 2024 from www.jrheum.org